EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • April 14th, 2022 • Quoin Pharmaceuticals, Ltd. • Surgical & medical instruments & apparatus • Nevada
This agreement (hereinafter "Agreement"), effective as of this 17th day of October, 2019 (hereinafter the “Effective Date”), is by and between the Skinvisible Pharmaceuticals, Inc. a Nevada corporation and having its principal place of business at 6320 South Sandhill Road, Suite 10, Las Vegas, Nevada, 89120 (“Skinvisible”) and Quoin Pharmaceuticals, Inc., a Delaware corporation having a place of business located at 42127 Pleasant Forest Court, Ashburn, VA, 20148 (hereinafter “Licensee”).
THIRD AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT RENEWALTheexclusive License Agreement • April 14th, 2022 • Quoin Pharmaceuticals, Ltd. • Surgical & medical instruments & apparatus
THIS AMENDMENT TO THE EXCLUSIVE LICENSE AGREMEMENT RENEWAL (this “Amendment”) is made and entered into as of January 27, 2021, by and among Skinvisible, Inc., a Nevada corporation (referred to as “SKINVISIBLE” ), and Quoin Pharmaceuticals, Inc., a Delaware corporation (“Licensee”).
MASTER SERVICE AGREEMENTMaster Service Agreement • April 14th, 2022 • Quoin Pharmaceuticals, Ltd. • Surgical & medical instruments & apparatus • Illinois
This Master Service Agreement, (“Master Agreement”) effective November 2, 2020 (“Effective Date”), is made by and between Therapeutics, Inc., a Delaware corporation with corporate offices located at 9025 Balboa Avenue, Suite 100, San Diego, CA 92123 (hereinafter “THERAPEUTICS” or “TI”) and Quoin Pharmaceuticals Ltd. with corporate offices located at 42127 Pleasant Forest Ct, Ashburn, VA 20148 (hereinafter “QUOIN”), singly referred to as a “Party” or collectively as the “Parties”.
SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT RENEWAL by and among SKINVISIBLE, INC., QUOIN PHARMACEUTICALS, INC., Dated as of May 8, 2020Exclusive License Agreement • April 14th, 2022 • Quoin Pharmaceuticals, Ltd. • Surgical & medical instruments & apparatus
THIS AMENDMENT TO THE EXCLUSIVE LICENSE AGREMEMENT RENEWAL (this “Amendment”) is made and entered into as of September 30, 2020, by and among Skinvisible, Inc., a Nevada corporation (referred to as “SKINVISIBLE” ), and Quoin Pharmaceuticals, Inc., a Delaware corporation (“Licensee”).
FIRST AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT by and among SKINVISIBLE, INC., QUOIN PHARMACEUTICALS, INC., Dated as of October 17, 2019Exclusive License Agreement • April 14th, 2022 • Quoin Pharmaceuticals, Ltd. • Surgical & medical instruments & apparatus
THIS AMENDMENT TO THE EXCLUSIVE LICENSE AGREMEMENT (this “Amendment”) is made and entered into as of July 31, 2020, by and among Skinvisible, Inc., a Nevada corporation (referred to as “SKINVISIBLE” ), and Quoin Pharmaceuticals, Inc., a Delaware corporation (“Licensee”).
EXCLUSIVE LICENSE AGREEMENT RENEWALExclusive License Agreement • April 14th, 2022 • Quoin Pharmaceuticals, Ltd. • Surgical & medical instruments & apparatus
THIS RENEWAL OF THE EXCLUSIVE LICENSE AGREMEMENT (this “Renewal”) is made and entered into as of May 8, 2020, by and among Skinvisible, Inc., a Nevada corporation (referred to as “SKINVISIBLE” ), and Quoin Pharmaceuticals, Inc., a Delaware corporation (“Licensee”).
FIFTH AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT RENEWALQuoin Pharmaceuticals, Ltd. • April 14th, 2022 • Surgical & medical instruments & apparatus
THIS AMENDMENT TO THE EXCLUSIVE LICENSE AGREMEMENT RENEWAL (this “Amendment”) is made and entered into as of June 14, 2021, by and among Skinvisible, Inc., a Nevada corporation (referred to as “SKINVISIBLE” ), and Quoin Pharmaceuticals, Inc., a Delaware corporation (“Licensee”).
FOURTH AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT RENEWALTheexclusive License Agreement • April 14th, 2022 • Quoin Pharmaceuticals, Ltd. • Surgical & medical instruments & apparatus
THIS AMENDMENT TO THE EXCLUSIVE LICENSE AGREMEMENT RENEWAL (this “Amendment”) is made and entered into as of April 19, 2021, by and among Skinvisible Pharmaceuticals, Inc., a Nevada corporation (referred to as “SKINVISIBLE” ), and Quoin Pharmaceuticals, Inc., a Delaware corporation (“Licensee”).
